Down-regulation of ICBP90 contributes to doxorubicin resistance

European Journal of Pharmacology

Volumn 656, Issue 1-3, 2011, Pages 33-38

  Wang, Jingxuan ^a   Song, Ying ^a   Xu, Shanqi ^a   Zhang, Qingyuan ^a   Li, Yulian ^a   Tang, Dabei ^a   Jin, Shi ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cell cycle arrest; Doxorubicin; ICBP90; Topo II

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FORSKOLIN; INVERTED CCAAT BOX BINDING PROTEIN 90; NUCLEIC ACID BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FORSKOLIN; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MIDDLE AGED; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 79952282937     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.01.042     Document Type: Article

References (30)

1. A.Q. Abbady, C. Bronner, M.A. Trotzier, R. Hopfner, K. Bathami, C.D. Muller, M. Jeanblanc, and M. Mousli ICBP90 expression is down-regulated in apoptosis-induced Jurkat cells Ann. NY Acad. Sci. 1010 2003 300 303 (Pubitemid 38264993)
2. Y. Arima, T. Hirota, C. Bronner, M. Mousli, T. Fujiwara, S. Niwa, H. Ishikawa, and H. Saya Downregulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1 dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition Genes Cells 9 2004 131 142 (Pubitemid 38312957)
3. G. Arpino, D.R. Ciocca, H. Weiss, D.C. Allred, P. Daguerre, L. Vargas-Roig, M. Leuzzi, F. Gago, R. Elledge, and S.K. Mohsin Predictive value of apoptosis, proliferation, HER-2, and topoisomerase II alpha for anthracycline chemotherapy in locally advanced breast cancer Breast Cancer Res. Treat. 92 2005 69 75 (Pubitemid 40875080)
4. I.M. Bonapace, L. Latella, R. Papait, F. Nicassio, A. Sacco, M. Muto, M. Crescenzi, and P.P. Di Fiore Np95 is regulated by E1A during mitotic reactivation of terminally differentiated cells and is essential for S phase entry J. Cell Biol. 157 2002 909 914 (Pubitemid 34839765)
5. N.E. Breslow, and N.E. Day Statistical methods in cancer research. Volume I - the analysis of case-control studies IARC Sci. Publ. 32 1980 5 338
6. C. Bronner, M. Achour, Y. Arima, T. Chataigneau, H. Saya, and V.B. Schini-Kerth The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol. Ther. 115 2007 419 434 (Pubitemid 47362377)
7. A.Y. Chen, and L.F. Liu DNA topoisomerases: essential enzymes and lethal drugs Annu. Rev. Pharmacol. Toxicol. 34 1994 191 218
8. A.M. Fry, C.M. Chresta, S.M. Davies, M.C. Walker, A.L. Harris, J.A. Hartley, J.R. Masters, and I.D. Hickson Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines Cancer Res. 51 1991 6592 6595
9. S. Geisler, A.L. Børresen-Dale, H. Johnsen, T. Aas, J. Geisler, L.A. Akslen, G. Anker, and P.E. Lønning TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer Clin. Cancer Res. 9 2003 5582 5588 (Pubitemid 37499478)
10. A.L. Harris, and D. Hochhauser Mechanisms of multidrug resistance in cancer treatment Acta Oncol. 31 1992 205 213
11. R. Hopfner, M. Mousli, J.M. Garnier, R. Redon, S. du Manoir, B. Chatton, N. Ghyselinck, P. Oudet, and C. Bronner Genomic structure and chromosomal mapping of the gene coding for ICBP90, a protein involved in the regulation of the topoisomerase II alpha gene expression Gene 266 2001 15 23 (Pubitemid 32268652)
12. R. Hopfner, M. Mousli, P. Oudet, and C. Bronner Overexpression of ICBP90, a novel CCAAT-binding protein, overcomes cell contact inhibition by forcing topoisomerase II alpha expression Anticancer Res. 22 2002 3165 3170 (Pubitemid 36070088)
13. M. Jeanblanc, M. Mousli, R. Hopfner, K. Bathami, N. Martinet, A.Q. Abbady, J.C. Siffert, E. Mathieu, C.D. Muller, and C. Bronner The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle Oncogene 24 2005 7337 7345 (Pubitemid 41622238)
14. U. Kellner, M. Sehested, P.B. Jensen, F. Gieseler, and P. Rudolph Culprit and victim - DNA topoisomerase II Lancet Oncol. 3 2002 235 243 (Pubitemid 34436660)
15. Y. Li, J. Pei, H. Xia, H. Ke, H. Wang, and W. Tao Lats2, a putative tumor suppressor, inhibits G1/S transition Oncogene 22 2003 4398 4405 (Pubitemid 36897970)
16. Q. Li, K. Kawamura, G. Ma, F. Iwata, M. Numasaki, N. Suzuki, H. Shimada, and M. Tagawa Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents Eur. J. Cancer 46 2010 180 190
17. K. Mehta High levels of transglutaminase expression in doxorubicin resistant human breast carcinoma cells Int. J. Cancer 58 1994 400 406 (Pubitemid 24254651)
18. T. Mori, Y. Li, H. Hata, K. Ono, and H. Kochi NIRF, a novel RING finger protein, is involved in cell-cycle regulation Biochem. Biophys. Res. Commun. 296 2002 530 536
19. J.E. Quinn, R.D. Kennedy, P.B. Mullan, P.M. Gilmore, M. Carty, P.G. Johnston, and D.P. Harkin BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res. 63 2003 6221 6228 (Pubitemid 37255167)
20. M.C. Scaini, E. Rossi, P.L. de Siqueira Torres, D. Zullato, M. Callegaro, C. Casella, M. Quaggio, S. Agata, S. Malacrida, V. Chiarion-Sileni, A. Vecchiato, M. Alaibac, M. Montagna, G.J. Mann, C. Menin, and E. D'Andrea Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation Mutat. Res. 671 2009 26 32
21. C.M. Schworer, K.K. Masker, G.C. Wood, and D.J. Carey Microarray analysis of gene expression in proliferating Schwann cells: synergistic response of a specific subset of genes to the mitogenic action of heregulin plus forskolin J. Neurosci. Res. 73 2003 456 464 (Pubitemid 36944838)
22. M. Stros, E. Polanská, S. Struncová, and S. Pospísilová HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase II alpha Nucleic Acids Res. 37 2009 2070 2086
23. D.M. Sullivan, M.D. Latham, and W.E. Ross Proliferation dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells Cancer Res. 47 1987 3973 3979 (Pubitemid 17108456)
24. Y. Takahashi, Y. Miyoshi, C. Takahata, N. Irahara, T. Taguchi, Y. Tamaki, and S. Noguchi Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers Clin. Cancer Res. 11 2005 1380 1385 (Pubitemid 40315216)
25. M.A. Trotzier, C. Bronner, K. Bathami, E. Mathieu, A.Q. Abbady, M. Jeanblanc, C.D. Muller, C. Rochette-Egly, and M. Mousli Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase II alpha expression Biochem. Biophys. Res. Commun. 319 2004 590 595 (Pubitemid 38725987)
26. J.G. Turner, D.C. Marchion, J.L. Dawson, M.F. Emmons, L.A. Hazlehurst, P. Washausen, and D.M. Sullivan Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition Cancer Res. 69 2009 6899 6905
27. M. Unoki, T. Nishidate, and Y. Nakamura ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain Oncogene 23 2004 7601 7610 (Pubitemid 39424918)
28. S. Withoff, S. De Jong, E.G. De Vries, and N.H. Mulder Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance Anticancer Res. 16 1996 1867 1880 (Pubitemid 26270698)
29. X. Ye, W. Zhou, Y. Li, Y. Sun, Y. Zhang, H. Ji, and Y. Lai Darbufelone, a novel anti-inflammatory drug, induces growth inhibition of lung cancer cells both in vitro and in vivo Cancer Chemother.Pharmacol 6 2010 277 285
30. H. Zhu, M. Huang, F. Yang, Y. Chen, Z.H. Miao, X.H. Qian, Y.F. Xu, Y.X. Qin, H.B. Luo, X. Shen, M.Y. Geng, Y.J. Cai, and J. Ding R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II Mol. Cancer Ther. 6 2007 484 495 (Pubitemid 46332450)